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Abstract
Background—The Department of Health and Human Services (HHS) Advisory Committee on 
Heritable Disorders in Newborns and Children (“Advisory Committee”) makes recommendations 
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to the HHS Secretary regarding addition of new conditions to the national Recommended Uniform 
Screening Panel for newborns. The Advisory Committee’s decision-making process includes 
assessing the net benefit of screening for nominated conditions, informed by systematic evidence 
reviews generated by an independent Condition Review Workgroup. The evidence base regarding 
harms associated with screening for specific conditions is often more limited than that for benefits.
Procedures—The process for defining potential harms from newborn screening reviewed the 
frameworks from other public health evidence-based review processes, adapted to newborn 
screening by experts in systematic review, newborn screening programs and bioethics, with input 
from and approval by the Advisory Committee.
Main findings—To support the Advisory Committee’s review of nominated conditions, the 
Workgroup has developed a standardized approach to evaluation of harms and relevant gaps in the 
evidence. Types of harms include the physical burden to infants; psychosocial and logistic burdens 
to families from screening or diagnostic evaluation; increased risk of medical treatment for infants 
diagnosed earlier than children with clinical presentation; delayed diagnosis from false negative 
results; psychosocial harm from false positive results; uncertainty of clinical diagnosis, age of 
onset or clinical spectrum; and disparities in access to diagnosis or therapy.
Conclusions—Estimating the numbers of children at risk, the magnitude, timing and likelihood 
of harms will be integrated into Workgroup reports to the Advisory Committee.
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Introduction
In 2004 the United States Department of Health and Human Services (HHS) established the 
Advisory Committee on Heritable Disorders in Newborns and Children (Advisory 
Committee) to make policy and practice recommendations to the HHS Secretary [1]. One of 
the Advisory Committee’s key activities is to evaluate the existing data and make 
recommendations to the HHS Secretary about addition of new conditions to the national 
Recommended Uniform Screening Panel (RUSP) for newborn screening. Nominated 
conditions must meet specified criteria in order to be recommended for addition to the 
RUSP, including the certainty and magnitude of the net benefit of screening for the proposed 
condition [2, 3]. An independent Condition Review Workgroup synthesizes the data 
regarding these criteria for the Advisory Committee using findings from systematic reviews 
of literature, decision-analytic modeling [4], and stakeholder input [3], organized around the 
available “chain of evidence” [2] regarding newborn screening, follow-up diagnostic 
services and treatment.
Net benefit is determined by considering if the overall impact of potential benefits and 
harms of population-based newborn screening for a condition for early diagnosis and 
initiation of treatment exceeds the benefits derived from clinical diagnosis of affected 
children in the absence of screening. The certainty and magnitude of net benefit includes 
measures of likelihood of outcomes and numbers of individuals affected.
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The goal of this report is to describe a framework for systematic assessment by the Advisory 
Committee of the actual or potential harms from newborn screening associated with 
conditions nominated for inclusion to the RUSP, either for the overall population screened or 
for specific sub-populations. An additional goal of the evidence review process is to identify 
research gaps related to harms [5], but not to find examples of previous harms from 
screening, if any. This framework has been integrated into the current evidence review 
process of examination of existing data [6, 7].
Methods
Other Established Public Health Assessments of Harm
Other well established deliberative groups have addressed the need to assess harms by 
creating methods to systematically categorize and assess the magnitude of potential harms 
related to preventative screening. For example, the U.S. Preventive Services Task Force 
(USPSTF) explicitly examines the existing data on harms of screening, diagnosis and 
treatment of each condition under consideration to make an overall determination of the 
“magnitude of net benefit” from screening for a specific condition or implementing a 
particular prevention strategy. Examination by the USPSTF includes an assessment of 
potential physical and psychological harms associated with both screening and early 
treatment, such as unnecessary diagnostic procedures derived from the false positives of a 
screening procedure [8]. The USPSTF generally searches broadly for publications of all 
harms, including study designs (e.g., case reports and case series) beyond those used to 
establish benefit of preventive services [8–10]. The U.S. Advisory Committee on 
Immunization Practices (ACIP) utilizes an explicit modeling approach to estimate the 
tradeoffs between benefits of vaccination (averted morbidity and mortality), potential harms 
of vaccine adverse events, and costs [11, 12].
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working 
group is tasked by the Office of Public Health Genomics of the Centers for Disease Control 
and Prevention with evaluating evidence related to the analytic and clinical validity and 
clinical utility of genetic and genomic tests. Their process includes a modeling of estimates 
of clinical events, including potential benefits and harms (e.g. false positive results) of 
testing to patients, as well as a consideration of life extension, when appropriate. However, 
the EGAPP process is hampered by the limited data available on both the benefits and harms 
of many genetic tests, including uncertainty regarding clinical validity or utility [13]. Other 
established public health evidence review groups have faced similar challenges of 
insufficient evidence about harm [14], and at times have explicitly incorporated expert 
opinion into their decisions [15].
Harris et al. [16] recently proposed a taxonomy of the harms resulting from screening for 
specific medical conditions, identifying four major domains of harms: physical, 
psychological, financial, and opportunity costs. That assessment identified how each of these 
types of harms may occur within the stages of the screening process, including screening, 
diagnostic evaluation, treatment and monitoring. Methods have been proposed to quantify 
harms associated with screening that highlight the need to distinguish physical from 
psychosocial impacts [17] and to identify harms that might occur at the different stages [17, 
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18], including long-term monitoring for those not being actively treated. The experience of 
these deliberative groups informs the process of assessing harms of newborn screening for 
new conditions.
Findings
Defining Harm in the Context of Newborn Screening
In newborn screening, a harm is any adverse impact (i.e. event, risk, or burden) resulting 
from screening or related follow-up with respect to the well-being of a newborn or the 
psychosocial health of the family, and can occur at any point within the stages of screening. 
Potential harms must be considered in comparison to usual clinical care. For example, a 
child affected by a certain condition would typically be diagnosed some time after the 
development of symptoms. Therefore, the impact of screening-related harms on diagnosis 
and treatment would be incremental over the harms that typically accrue once the condition 
is diagnosed through a clinical evaluation. Other potential harms to newborns include 
findings that do not confer any clinical benefit, such as the identification of infants with 
clinically silent genetic variants.
For any given harm, several features should be considered when assessing its impact: 
number of children at risk, its severity, timing and likelihood. Additionally, because the 
actual risk and impact of identified harms may be largely unknown at the time of evidence 
review, consideration for “potential harms” is implicit in this evaluation.
Policy makers considering expanding NBS panels should also evaluate the opportunity costs 
for state public health programs due to the resources or trade-offs required for 
implementation [19]. While this type of harm is relevant to the broader context of NBS 
programs and the universal accessibility of its benefits, our focus is on the impacts of 
screening on newborns and their families. As part of the condition review process, the 
Condition Review Workgroup conducts a separate public health system impact assessment 
that includes an assessment of the resources required to expand newborn screening [3].
The Challenges of Assessing Harms in Newborn Screening
The evidence review process for each condition proposed for the RUSP focuses on 
identifying key elements for consideration by the Advisory Committee concerning the net 
benefits of screening and initiation of treatment for an affected child to optimize outcomes 
of the disorder [2]. The process for nominating conditions requires some documentation or 
probability of benefit to screening for that condition. In contrast, data on anticipated or 
demonstrated harms for the Advisory Committee’s consideration may be a lesser focus 
within the nomination process. Moreover, data on harms also may be less available or 
apparent. For example, the modest number of subjects often participating in clinical trials 
related to rare disorders or a lack of randomized trials or multiple open label studies may 
lead to an insufficient evidence base to delineate the range of potential harms or to estimate 
their likelihood [20]. Limitations of data about harms may also result from studies 
constrained by difficulties in subject recruitment, such as pediatric or neonatal intervention 
trials concerning life-threatening conditions or selectivity in subject enrollment for studies in 
which at-risk newborns were identified through affected older siblings rather than through 
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population-based screening [21], or if populations previously screened are not representative 
of the heterogeneous population of the United States [22].
Challenges to detecting, measuring or reporting harms are not exclusive to NBS. Research 
on the implementation of new medical tests or interventions tend to primarily focus on 
medical benefit. Consequently, data on harms from clinical studies of tests may be 
underappreciated, especially if harms are unexpected, delayed, cumulative, non-medical 
(e.g. psychological) [7, 23–25], or if they accrue primarily in persons who do not have the 
targeted disease.
Assessing Harms Associated with Screening for a Specific Condition
The Condition Review Workgroup utilizes a set of key questions to explore relevant 
considerations for all aspects of screening for a particular condition as compared to usual 
care (i.e., clinical diagnosis) [2]. These questions are evaluated through a variety of 
approaches, including systematic review, surveys, or decision-analytic modeling. As part of 
the Workgroup’s consideration of net benefits, harms are assessed through three sets of key 
questions that relate to the potential harms of screening, diagnosis and treatment associated 
with the screening of newborns for a particular condition [2, 3].
Characterizing these harms (Table 1) will support their explicit assessment in condition 
evidence review, as well as to identify associated research gaps. Assessment of harms 
includes: (1) Description and characterization of the harm identified through the available 
data and expert review process: (2) Assessment of the incidence, likelihood and magnitude 
of each identified harm; (3) Determination of who may be harmed, whether distributed to 
the entire newborn population or to sub-populations, or to families.
Harms Associated with Newborn Screening
Physical Pain or Medical Risk Associated with Screening—The dried-blood spot 
collection process involves a heel stick and is not a significant harm associated with adding 
another condition to screening panels because it is already a routine practice for other 
newborn screening tests. Beyond routine dried bloodspot collection, a harm may be 
identifiable as a painful acquisition of a sample if screening for a particular condition 
required additional sampling of blood or tissue sampling. For proposed point-of-care 
screening, pain or medical risk would arise if data collection would include any invasive 
practice previously not applied routinely to newborns [26], such as the use of an instrument 
that causes discomfort, requires sedation or is associated with another medical risk (e.g. 
radiation exposure from a medical scanner or a burn from a skin probe).
Missed Infants with True Diagnosis (Clinical “False Negatives”) Associated 
with Screening—The potential for delay in clinical diagnosis may result from false 
negative results from screening tests. Diagnostic delay from false negatives may arise by 
steering the diagnostic evaluation away from the true condition due to false reassurance of 
clinicians and families, especially if they are unaware of the potential for false negative 
results. While newborn screening overall attempts to minimize false negatives through the 
methodology for developing quality control of screening algorithms [27, 28], screening or 
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diagnostic tests for some conditions, including point-of-care screening, may have relatively 
low sensitivity [29]. In addition to the fundamental challenges of using screening tests to 
discriminate populations with overlapping distributions of test characteristics, false negatives 
can arise from a number of clinical or laboratory practices. These practices include 
collecting the screening sample outside of the optimal time window, clinical intervention 
prior to sample collection (e.g. transfusion), sample collection or handling error, analytic 
insensitivity (e.g. cut-off values that differ by phenotype or ethnicity), incorrect 
interpretation of results or poor genotype-phenotype correlations in newborns [27, 30, 31].
Positive Laboratory Results Associated with Unaffected Infants (Clinical 
“False Positives”)—Positive screening results for an unaffected infant (“false positive”) 
or screening for condition with a long interval between a positive screening result and 
confirmatory diagnostic testing may induce considerable short-term parental anxiety [32–
36]. Potential psychosocial or nonphysical harms include “the possibility for stigmatization, 
unnecessary anxiety, adverse impacts on parent and family relationships, and other ethical, 
legal, and social implications” [2]. Newborn hearing screening and other point-of-care 
testing paradigms may be especially prone to false positive results [37].
To date, falsely identifying unaffected infants due to positive screening results may have 
been the most commonly identified harm to families from newborn screening. The etiology 
of falsely identifying unaffected infants is inherent in the trade-off between laboratory cut-
offs for screening sensitivity (needing to approach 100 %) and specificity. The impact of 
false identification unfolds with the need to verify laboratory results from newborns who are 
later determined to be trait carriers, born to affected mothers, or have clinical factors such as 
acute illness, prematurity, hyperalimentation, or transfusion. Although there is anecdotal 
evidence of parental concerns following positive screening results from unaffected infants, 
evidence of long-term harm is generally lacking [32]. Harms to the newborn screening 
system from frequent false identification may also arise, such as provider laxity about 
prompt re-testing and referral for infants, inclusive of those later determined to have true 
positive results [38], and burdens on public health and clinical staff [39].
Potential Harms Associated with Diagnostic or Prognostic Procedures
Physical Pain or Medical Risk Associated with Diagnostic Evaluation—Harm 
may arise from diagnostic processes that require invasive medical procedures (e.g. skin 
biopsies), or risky procedures such as anesthesia or radiation exposure due to diagnostic 
procedures (e.g. CT scans). Diagnostic processes that are performed on an affected infant or 
child prior to treatment would not generally be included as an incremental harm because the 
affected infant would be expected to be subjected to these (and other) tests with clinical 
presentation. The differential harm from screening would arise for infants with false positive 
screens who would not normally have undergone the testing, or for whom clinically 
indicated diagnostic testing would be at an older age when, in some cases, testing would be 
less onerous or risky.
Psychosocial Harm from Diagnostic or Prognostic Uncertainty—Newborn 
screening identifies infants at risk for a particular condition, with the expectation that 
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diagnostic evaluation will be confirmed or ruled out. However, family anxiety may arise 
through diagnostic uncertainty when a standard clinical evaluation requires signs or 
symptoms typically observed in an infant or child who has had more disease progression 
(e.g. Krabbe disease) [40]. Uncertainty can arise due to broad phenotypic expression, poor 
genotype–phenotype correlation with a spectrum of disease manifestations, or delayed age 
of onset. Harms associated with uncertainty also include the possibility of abandoning the 
true diagnosis to follow other disorders, in addition to psychological harm to the child as 
well as to their family. Such harms could stem from requirement for monitoring for disease 
manifestations (e.g. Krabbe disease) [40], anxiety, reproductive issues for parents, and 
decisions pertaining to treatment, health care utilization, insurance, location, and infant–
parent bonding [41–44]. Family anxiety may also arise from diagnostic or prognostic 
uncertainty when a decision needs to be made about particularly risky treatment (e.g. 
hematopoietic stem cell transplantation). These uncertainties may be short-lived or may 
persist and require long-term monitoring. A similar range of harms may arise from the 
medical futility of disorders for which no treatment currently exists if diagnosis were derived 
from incidental findings of screening [45].
Potential Harms Associated with Treatment
Physical Pain or Medical Risk Associated with Treatment—Standard care for an 
affected infant would not generally be included as differential harm associated with 
screening because treatment of an affected infant would be expected. Treatment of infants 
diagnosed by screening could occur earlier than for children diagnosed clinically. Although 
earlier treatment may be more effective, younger children may be more vulnerable to 
treatment-associated harms.
The potential adverse events or complications associated with a standard treatment should be 
included as a potential harm within our framework if the treatment is also likely to be 
offered to (1) test positive but clinically unaffected infants; (2) affected infants whose 
disease phenotype renders treatment as less effective or who might not require treatment; (3) 
younger children who may have greater vulnerability to adverse effects of treatment; or (4) 
children for whom risks from treatment would otherwise be substantially delayed due to 
later onset disease manifestation. In these scenarios, treatment harms could result if 
screening leads to medically risky treatment for children who would otherwise not have 
undergone those treatments, which is more likely for conditions with a broad spectrum of 
disease intensity, poor genotype–phenotype correlation, or variable age of onset. Substantial 
harms may occur if treatment is painful, medically risky or even life-threatening, such as 
hematopoietic stem cell transplantation or other major biologic therapy, or medications with 
narrow therapeutic windows or serious adverse effects.
Psychosocial Harm from Treatment Decisions—Harm may include family distress 
related to adverse disease outcomes if declining treatment (e.g., family refuses 
presymptomatic therapy because of their perceived risk of treatment), or if treatment is 
delayed or is not available despite disease progression (e.g., no matched donor for stem cell 
transplantation, expensive or complex treatment is not available in the local community).
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Increased Health Disparities—Newborn screening has led to reduced health disparities 
through universal access to early diagnosis [46]. Nonetheless, differing access to treatment 
could exacerbate health disparities associated with screening. Disparities could result from 
differential access to or insurance coverage of diagnostic procedures or treatment centers if 
the impact is anticipated to be greater under newborn screening compared with clinical 
presentation. For example, a child may not have access to highly specialized diagnostic 
testing or treatment such as transplantation within their state, or if their insurance does not 
cover certain procedures when performed out-of-state. Additional disparities could also 
result if diagnostic testing or treatment being used were differentially effective depending on 
the ethnicity of the child. These disparities may also arise through the clinical diagnosis of a 
child affected by the condition.
Assessing the Impact of Harms
The potential impact of harms depends on several key considerations: (1) the number of 
children and/or families at risk of harm, (2) severity of those potential harms for each child 
or family, (3) certainty or likelihood that a particular harm would happen, and (4) the timing 
of when the harm would occur. Similar aspects pertaining to impact on families may be 
taken into account within the context of evidence review. Generating a precise estimate of 
impact of a particular harm based on these four considerations may be difficult given the 
lack of data available regarding the harms of screening for a particular condition. In most 
cases, estimating the impact of harms will require extrapolation from scant data. Despite 
considerable uncertainty, at a minimum the process of explicit data review and identification 
of data gaps is intended to enhance the transparency of assessing net benefit by identifying 
the gaps in evaluable data. State- or other population-based programs that pilot the screening 
of nominated conditions are expected to help address some of the research gaps, even as 
states may need to address variability in the context of their own geographic and/or 
population base. This framework may inform data collection from these and other studies 
pertaining to screenable conditions.
Integrating Harms into the Modeling Process to Assess Net Benefit
The process of identifying harms and assessing their impact as described here can be 
explicitly incorporated into the established system of decision analytic modeling that is used 
by the Condition Review Workgroup for determining the potential of net benefit [4]. This 
modeling process, adapted from those in use by the USPTF and the ACIP [8–12], aids in the 
estimation of net benefit by utilizing an approach to determine the upper and lower bounds 
of foreseen benefit on the population of newborns [4]. The refinement described here 
provides a framework to model estimates of potential harms, with estimates for each of the 
features that modulate the impact or magnitude of those harms when sufficient data are 
available.
In light of the expected paucity of completeness of data on harms, we acknowledge that 
formal quantitative addition of harms to the existing modeling paradigm may be more 
challenging for some nominated conditions, depending upon the nature and degree of data 
gaps. Like the USPSTF, the Condition Review Workgroup has recognized that it can be 
challenging to quantify with precision the magnitude of harms from any specific preventive 
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measure. Nonetheless, that group has integrated the use of boundaries into their assessment 
of net benefits that rely on estimates of best and worst case scenarios regarding screening 
outcomes [8].
Conclusions
Developments in knowledge and technologies are facilitating opportunities to increase the 
benefit of newborn screening through the potential expansion of the RUSP. Nominated 
conditions are heterogeneous in risks associated with the screening test, diagnostic 
algorithm, disease manifestation, and response to treatment. Benefits to screening for early 
initiation of treatment are typically enjoyed by a small number of individuals for rare or 
unusual conditions.
Condition Review Workgroup reports to the Advisory Committee about conditions 
nominated to the RUSP require the systematic collection and synthesis of available data on 
the associated benefits and harms of implementation. Integrating the refined framework 
described here for assessing potential harms associated with nominated conditions into the 
current condition review process is intended to add to the published procedures used by the 
Advisory Committee in assessing the overall net benefits of screening for newborns and 
families through the identification and characterization of harms, modeling of their impact at 
the population level for those harms that can be adequately quantified, and the identification 
of research gaps.
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Through systematic evidence review, the Health and Human Services Advisory 
Committee on Heritable Disorders in Newborns and Children assesses the net benefit of 
each condition considered for addition to the national recommended uniform screening 
panel for newborn screening. We describe the standardized approach adopted by the 
Advisory Committee to evaluate harms and relevant gaps in the evidence for nominated 
conditions. This approach is based on consideration of other public health evidence-based 
review processes, expertise in newborn screening and bioethics.
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Table 1
Potential harms associated with newborn screening
Aspect of newborn
screening
Type of potential harm
Newborns Parents/families
Screening (bloodspot or point-
of-care)
Pain or other adverse impacts from screening
False positives or false negatives of screening
Psychosocial harms associated with false positive 
laboratory results for unaffected infants
Diagnosis evaluation Pain or other adverse impacts from diagnostic testing
Missed or incorrect diagnosis
Disparities in access to diagnostic testinga
Psychosocial harm from diagnostic or prognostic 
uncertainty in diagnosis, or degree or age of onset 
of disease manifestations
Treatment and long term follow-
up
Pain or other adverse impacts of treatment
Treatment with an uncertain impact of disease 
severity and/or the timing of manifestations
Disparities in access to treatmenta
Psychosocial harm from uncertainty of outcomes
Psychosocial, financial or other harms associated 
with long-term treatment
Psychosocial harm from treatment decisions
a
Such disparities could be considered a harm if disparities associated with screening were more pronounced than those encountered with clinical 
presentation
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